

Osteoporose: Therapie-Update 2013, Teil 1

Therapieindikationen und praktisches Vorgehen

Ostéoporose: Mises à jour 2013 concernant le traitement, 1^{ère} partie

Indications thérapeutiques et procédé pratique

Literatur / Références

1. Rachner, T.D., S. Khosla, and L.C. Hofbauer, Osteoporosis: now and the future. *Lancet*, 2011. 377(9773):1276–87.
2. Lippuner, K., H. Johansson, J.A. Kanis, and R. Rizzoli, Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. *Osteoporos Int*, 2009. 20(7):1131–40.
3. SVGO, SVGO-Empfehlungen Osteoporose. Diagnostik, Prävention, Behandlung. 2010.
4. Kanis, J.A., N. Burlet, C. Cooper, P.D. Delmas, J.Y. Reginster, F. Borgstrom, et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int*. 2008;19(4):399–428.
5. Dachverband Osteologie, e.V., DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. *Osteologie*, 2011. 20: p. 55–74.
6. Kraenzlin, M.E. and C. Meier, Schlaglichter 2010: Neue Wege in der Diagnostik und Therapie der Osteoporose. *Swiss Med Forum*, 2011. 11(3): p. 25–28.
7. Kanis, J.A., A. Oden, H. Johansson, F. Borgstrom, O. Strom, and E. McCloskey, FRAX and its applications to clinical practice. *Bone*, 2009. 44(5): p. 734–43.
8. Lippuner, K., H. Johansson, J.A. Kanis, and R. Rizzoli, FRAX assessment of osteoporotic fracture probability in Switzerland. *Osteoporos Int*, 2010. 21(3): p. 381–9.
9. Kanis, J.A., E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, and A. Oden, Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. *Osteoporos Int*, 2008. 19(10): p. 1395–408.
10. Compston, J., A. Cooper, C. Cooper, R. Francis, J.A. Kanis, D. Marsh, et al., Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. *Maturitas*, 2009. 62(2): p. 105–8.
11. Briot, K., B. Cortet, T. Thomas, M. Audran, H. Blain, V. Breuil, et al., 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. *Joint Bone Spine*, 2012. 79(3): p. 304–13.
12. Kanis, J.A., E.V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli, J.Y. Reginster, et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int*, 2013. 24(1): p. 23–57.
13. Lewiecki, E.M. and N.B. Watts, New guidelines for the prevention and treatment of osteoporosis. *South Med J*, 2009. 102(2): p. 175–9.
14. Donaldson, M.G., P.M. Cawthon, L.Y. Lui, J.T. Schousboe, K.E. Ensrud, B.C. Taylor, et al., Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. *J Bone Miner Res*, 2009. 24(4): p. 675–80.
15. Lippuner, K., H. Johansson, F. Borgstrom, J.A. Kanis, and R. Rizzoli, Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. *Osteoporos Int*, 2012. 23(11): p. 2579–89.
16. Suhm, N., O. Lamy, and K. Lippuner, Management of fragility fractures in Switzerland: results of a nationwide survey. *Swiss Med Wkly*, 2008. 138(45–46): p. 674–83.
17. Kraenzlin, M.E. and C. Meier, Parathyroid hormone analogues in the treatment of osteoporosis. *Nat Rev Endocrinol*, 2011. 7(11): p. 647–56.
18. Black, D.M., D.C. Bauer, A.V. Schwartz, S.R. Cummings, and C.J. Rosen, Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? *N Engl J Med*, 2012. 366(22): p. 2051–3.
19. Black, D.M., A.V. Schwartz, K.E. Ensrud, J.A. Cauley, S. Levis, S.A. Quandt, et al., Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *Jama*, 2006. 296(24): p. 2927–38.

20. Black, D.M., I.R. Reid, S. Boonen, C. Bucci-Rechtweg, J.A. Cauley, F. Cosman, et al., The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res*, 2012. 27(2): p. 243–54.
21. McClung, M., S.T. Harris, P.D. Miller, D.C. Bauer, K.S. Davison, L. Dian, et al., Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. *Am J Med*, 2013. 126(1): p. 13–20.
22. McClung, M.R., E.M. Lewiecki, M.L. Geller, M.A. Bolognese, M. Peacock, R.L. Weinstein, et al., Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. *Osteoporos Int*, 2013. 24(1): p. 227–35.